Last updated on May 2019

A Safety and Pharmacokinetic Study Between HLX02 and Herceptin (U.S. and German) in Healthy Chinese Male Subjects

Brief description of study

Assessment of safety of HLX02 at different doses. Randomised, double-blind, parallel group Phase I study to compare PK profiles and to assess the safety and immunogenicity between HLX02 and Herceptin (U.S. and German).

Clinical Study Identifier: NCT02581748

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.